P. Nikolinakos

S. Ou, V. Miller, Siraj M. Ali, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Atypical Chemokine Receptor 1 (DARC/ACKR1) in Breast Tumors Is Associated with Survival, Circulating Chemokines, Tumor-Infiltrating Immune Cells, and African Ancestry

L. Newman, R. Kittles, H. Ali, 2019, Cancer Epidemiology, Biomarkers & Prevention.

Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1α in non-small cell lung cancer cells

J. Minna, A. Gazdar, I. Wistuba, 2010, Oncogene.

Amendment history : Corrigendum ( October 2009 ) HIF 2 a cooperates with RAS to promote lung tumorigenesis in mice

D. Hayes, Kwok-Kin Wong, W. Kaelin, 2018 .

HIF2α cooperates with RAS to promote lung tumorigenesis in mice (Journal of Clinical Investigation (2009) 119, (2160-2170) doi:101172/JCI38443)

D. Hayes, Kwok-Kin Wong, W. Kaelin, 2009 .

Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial

Edward J. Kim, H. Lenz, S. Kopetz, 2022, The oncologist.

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

C. Obasaju, R. Govindan, D. Spigel, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Altered regulation of HIF-1α in naïve- and drug-resistant EGFR mutant NSCLC: implications for a VEGF-dependent phenotype.

Jing Wang, J. Minna, I. Wistuba, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety, Efficacy and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients with EGFR-mutated Advanced NSCLC: a Multicenter, Open-label, Phase I Trial.

C. Chiu, T. Hsia, D. Camidge, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.

D. Yankelevitz, N. Altorki, H. Tran, 2010, Cancer research.

Simultaneous biochemical and functional phenotyping of single circulating tumor cells using ultrahigh throughput and recovery microfluidic devices.

L. Mao, Rui Cheng, P. Nikolinakos, 2021, Lab on a chip.

Tumor antigen-independent and cell size variation-inclusive enrichment of viable circulating tumor cells.

L. Newman, J. Murrow, L. Mao, 2019, Lab on a chip.

Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma

S. de Vos, Y. Oki, C. Deng, 2021, Experimental Hematology & Oncology.

High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy.

R. O'Regan, M. Torres, P. Nikolinakos, 2015, Clinical breast cancer.

A Phase I/II Study of Rovalpituzumab Tesirine in Combination With Nivolumab ± Ipilimumab in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer.

Melissa L. Johnson, G. Curigliano, D. Morgensztern, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab

J. Kolesar, D. Mahadevan, C. Deng, 2017, British journal of haematology.

Genomic mutation profiling (GMP) and clinical outcome of patients treated with buparlisib (PI3K inhibitor) in the “Signature” program.

S. Papish, S. Piha-Paul, B. Hellerstedt, 2015 .

Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial.

R. Motzer, J. Hsieh, Chung-Han Lee, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Autoimmune hemolytic anemia in patients infected with human immunodeficiency virus‐1

P. Nikolinakos, P. Singa, Prasad Rao Koduri, 2002, American journal of hematology.

92MO Neoadjuvant nivolumab (NIVO) + palbociclib (PALBO) + anastrozole (ANA) for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) primary breast cancer (BC): CheckMate 7A8

G. Jerusalem, S. Tolaney, F. Ades, 2022, Annals of Oncology.

Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153

S. Agrawal, T. Mekhail, D. Spigel, 2018, Cancer Chemotherapy and Pharmacology.